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Abstract
Background: Anaemia has been shown in previous studies to be a risk factor for cardiovascular
disease in diabetic patients with chronic kidney disorder. This study was aimed to assess the
prevalence of anaemia and kidney dysfunction in Caribbean type 2 diabetic patients that have been
previously shown to have a high prevalence of the metabolic syndrome.
Methods: 155 type 2 diabetic patients and 51 non-diabetic subjects of African origin were studied.
Anthropometric parameters were measured and fasting blood samples were collected for glucose,
creatinine, glycated hemoglobin and complete blood count. Anaemia was defined as haemoglobin
< 12 g/dl (F) or < 13 g/dl (M). Kidney function was assessed using glomerular filtration rate (GFR)
as estimated by the four-variable Modification of Diet in Renal Disease (MDRD) study equation.
Subjects were considered to have chronic kidney disease when the estimated GFR was < 60 ml/
min per 1.73 m2. Comparisons for within- and between-gender, between diabetic and non-diabetic
subjects were performed using Student's t-test while chi-square test was employed for categorical
variables.
Results: The diabetic patients were older than the non-diabetic subjects. While male non-diabetic
subjects had significantly higher red blood cell count (RBC), haemoglobin and hematocrit
concentrations than non-diabetic female subjects (p < 0.001), the RBC and hematocrit
concentrations were similar in male and female diabetic patients. Furthermore, irrespective of
gender, diabetic patients had significantly higher prevalence rate of anemia than non-diabetic
subjects (p < 0.05). Anaemic diabetes patients had significantly lower GFR (67.1 ± 3.0 vs. 87.9 ± 5.4
ml/min per 1.73 m2, p < 0.001) than non-anaemic patients.
Conclusion: A high prevalence of anaemia was identified in this group of type 2 diabetic patients
previously shown to have a high prevalence of the metabolic syndrome. It is therefore
recommended that diagnostic laboratories in developing countries and elsewhere should include
complete blood count in routine laboratory investigations in the management of diabetic patients.
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Introduction
Trinidad and Tobago has high prevalence of diabetes mel-
litus that the International Diabetes Federation has pro-
jected that by the year 2025, 11.8% of the population will
be diagnosed with type 2 diabetes [1]. Although the pro-
jected prevalence rate represents one of the highest preva-
lence rates in the North American region [1], of greater
concern are the several reports of poor glycaemic control
amongst type 2 diabetic patients at the primary care set-
tings in this population [2-4]. Poor glycaemia control,
obesity, sedentary lifestyle etc are some of the factors that
have been implicated in the increased risk of cardiovascu-
lar disease amongst diabetic patients in this population
[2,5]. Unfortunately, most of the published data from this
population have not assessed the impact of anaemia in
the risk of cardiovascular disease in type 2 diabetic
patients [2-5]. Yet, there are pathophysiologic reasons
why the presence of anaemia may lead to adverse cardio-
vascular consequences especially in diabetic patients. For
instance, it has been demonstrated that patients with
chronic anaemia had a high cardiac output and a low sys-
temic vascular resistance [6]. In the long term, this may
result in maladaptive left ventricular hypertrophy (LVH),
which is a known risk factor for adverse cardiovascular
outcome and all-cause mortality [7,8]. Furthermore, anae-
mia has been shown to be a risk factor for adverse cardio-
vascular outcomes in non-diabetic [9,10] and diabetic
patients [11] with chronic kidney disease. Therefore, given
that diabetes is a leading cause of kidney disease and kid-
ney failure, assessment of anaemia and kidney dysfunc-
tion in diabetic patients should be a regular laboratory
tests. This is particularly important given that anaemia
presents earlier and often more severe in diabetic patients
with chronic kidney disease compared with chronic kid-
ney disease patients without diabetes [12,13]. Although
there is scanty reports on the prevalence of kidney disease
in type 2 diabetic patients in this population, report of
end-stage renal disease that presented with chronic anae-
mia has been documented [14]. Thus, the presence of ane-
mia in diabetic patients with undetected renal
dysfunction may be particularly dangerous especially at
the primary care setting where routine laboratory investi-
gations are infrequent and haematological tests not usu-
ally included as part of the laboratory tests for the
patients' management. In this regard, the present study is
aimed to assess the prevalence of anaemia and kidney dys-
function in a cross-section of Afro-Caribbean type 2 dia-
betic patients that were previously shown to have a high
prevalence of the metabolic syndrome [15].
Subjects and methods
Type 2 diabetic patients
One hundred and fifty-five (46 males, 109 females) type
2 diabetic patients visiting, consecutively, eight lifestyle
disease clinics at primary care setting in Tobago (between
June and November 2006) participated in the study.
Patients were considered as type 2 diabetic if they had
been managed on oral hypoglycaemic medication and/or
diet/exercise since diagnosis (except on occasions when
patients took insulin to control hyperglycaemia). The pro-
tocol was as previously published [15]. Briefly, the
patients received information leaflets and posters explain-
ing the objectives and protocol of the research study and
a member of the research group addressed the patients
during the clinics to explain the rationale for the study.
Subsequently, the Research Assistant or Clinic Nurse took
names and other information of patients who volun-
teered to participate in the study. The patients were subse-
quently reminded of the importance of overnight fasting
a day preceding the study.
Non-diabetic subjects
Fifty-one (22 males, 29 females) apparently healthy non-
diabetic subjects living in the same environment/city
(Tobago) with the diabetic patients qualified to partici-
pate in the study as non-diabetic control subjects. Each
volunteer underwent compulsory oral glucose tolerance
tests (OGTT, 75 g anhydrous glucose in 250–300 ml
water) to detect undiagnosed diabetes (fasting plasma
glucose > 7.0 with 2-hour plasma glucose > 11.1 mmol/L)
and impaired glucose tolerance (2-hour plasma glucose >
7.8 mmol/L) [16]. Subjects with plasma glucose values
diagnostic of diabetes were excluded from the study and
data analysis while subjects with plasma glucose values
diagnostic of IGT were included in the study and data
analysis.
Study protocol
Informed consent was obtained from both the diabetic
and non-diabetic subjects that participated in the study.
The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori
approval by our institutional Ethics Review Committee.
All subjects were studied at the clinics in the morning after
an overnight (12–14 hours) fast. Details of self-reported
ethnic origin and age were directly ascertained from the
patients and recorded. Then, waist (cm), at the level of the
umbilicus with the patient standing and breathing nor-
mally, and hip circumferences (cm), at the level of the
largest projection of the buttocks, were obtained by tape
measure while weight (kg), with standard hospital bal-
ance, and height (m), with metal rule, were measured (in
light clothing, without shoes). Then, fasting blood sample
was collected from each subject and, for the non-diabetic
subjects alone, 75 g anhydrous glucose in 250–300 ml
water was given to each subject and blood samples col-
lected every 30 minutes for 120 minutes. Blood samples
were preserved in appropriate tubes for complete blood
count, creatinine, glucose and glycated haemoglobin
measurements.Cardiovascular Diabetology 2008, 7:25 http://www.cardiab.com/content/7/1/25
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Laboratory analysis
Plasma glucose and serum creatinine were measured in
multi-channel auto-analysers using dry slide kits (John-
son & Johnson Vitros 250, Ortho-Clinical Diagnostics
Inc., Rochester NY, USA). Glycated haemoglobin (HbA1c)
was determined using boronate affinity assay (Axis-Shield
PoC AS, N-0504 Oslo, Norway) while complete blood
count was measured using the routine Coulter counter
machine (Sysmex XE 2100, Germany).
Definitions, calculations and statistics
The results are expressed as mean ± SE. The Statistical
Package for the Social Sciences (SPSS Inc., Chicago, USA)
software was used in all analyses. Anemia was defined as
haemoglobin < 12 g/dl in females and < 13 g/dl in males
[17]. Kidney function was assessed using glomerular fil-
tration rate (GFR) as estimated by the four-variable Mod-
ification of Diet in Renal Disease (MDRD) study equation
as follows: GFR = 186.3 × (serum creatinine-1.154) × (age-
0.203) × 1.212 (if black) × 0.742 (if female). GFR was
expressed in ml/min/1.73 m2 [18] and patients were con-
sidered to have chronic kidney disease when the esti-
mated GFR was < 60 ml/min per 1.73 m2  [11].
Comparisons within- and between-gender, between dia-
betic and non-diabetic subjects were performed using Stu-
dent's t-test while chi-square test was employed for
categorical variables. A p-value < 0.05 was considered sta-
tistically significant on two-tailed testing for all analysis.
Results
Table 1 shows the clinical characteristics of all the subjects
studied. The diabetic patients were significantly older
than the non-diabetic subjects (p < 0.001). Compared
with non-diabetic subjects, lower percentage of the dia-
betic patients smoke cigarettes and drink alcoholic bever-
ages (Table 1, p < 0.05). The male non-diabetic subjects
had significantly higher red blood cell count (RBC),
hemoglobin (Hb) and hematocrit levels than their dia-
betic counterparts (Table 2, p < 0.001). However, the
female diabetic and non-diabetic subjects had similar Hb
concentrations (12.1 ± 0.1 vs. 12.5 ± 0.2 g/dl, p > 0.05).
While male non-diabetic subjects had significantly higher
RBC, Hb and hematocrit than non-diabetic female sub-
jects (p < 0.001), the RBC and hematocrit concentrations
were similar in male and female diabetic patients (Table
2, p > 0.05). The prevalence of anemia and chronic kidney
disease in the subjects are shown on Table 3. Irrespective
of gender, diabetic patients had significantly higher prev-
alence rate of anemia than non-diabetic subjects (Table 4,
p < 0.05). Again, diabetic patients had significantly higher
prevalence of kidney dysfunction compared with the non-
diabetic subjects (Table 4, p < 0.05). The diabetic patients
with anemia had significantly higher serum creatinine lev-
els (1.4 ± 0.1 vs. 1.0 ± 0.03 mg/dl, p < 0.001) and lower
GFR (67.1 ± 3.0 vs. 87.9 ± 5.4 ml/min per 1.73 m2, p <
0.001) than diabetic patients without anemia. Similarly,
diabetic patients with anaemia had significantly higher
levels of glycated hemoglobin (index of blood glucose
control), creatinine and higher prevalence of kidney dys-
function than non-diabetic subjects with anaemia (Table
3, p < 0.05).
Discussion
This study has shown that anaemia was more prevalent in
diabetic than non-diabetic subjects irrespective of gender,
and diabetic patients with anaemia had the lowest kidney
function compared with patients without anaemia or
non-diabetic subjects with anaemia. The implications of
these findings in relation to diabetes management are fur-
ther discussed.
All the new frontiers in the management of type 2 diabetes
are aimed at achieving optimal blood glucose control so
as to prevent macro- and micro-vascular complications
[19-22]. In the primary care setting in the clinics studied,
assessment of haematological parameters is no part of
Table 1: Clinical characteristics of the diabetic and non-diabetic subjects studied
Variables Type 2 diabetic patients Non-diabetic subjects
Gender (m/f ratio) 46/109 22/29
Age (yr) 65.9 ± 0.9 48.8 ± 1.2**
Duration of diabetes (yr) 10.6 ± 0.7 -
Weight (kg) 77.9 ± 1.2 83.3 ± 2.0*
Height (m) 1.64 ± 0.01 1.68 ± 0.01*
Body mass index (kg/m2) 28.6 ± 0.4 30.2 ± 0.8
Waist circumference (cm) 99.1 ± 1.0 95.5 ± 1.4
Hip circumference (cm) 105.0 ± 0.8 108.8 ± 1.4*
Unemployed (%) 112 (72.3) 3 (5.9)**
Cigarette smokers (%) 6 (3.9) 6 (11.8)*
Alcohol users (%) 29 (18.7) 23 (45.1)**
*P < 0.05, **P < 0.001 for comparisons between diabetic and non-diabetic subjectsCardiovascular Diabetology 2008, 7:25 http://www.cardiab.com/content/7/1/25
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routine diabetic evaluation. Therefore, the finding in this
study of high prevalence rates of anaemia amongst the
diabetic patients studied, irrespective of gender, is per-
haps, the first report in the Caribbean diabetic popula-
tion. This finding is significant given that anaemia has
previously been shown to be associated with cardiovascu-
lar disease and all-cause mortality in diabetic patients
[11]. However, other workers have reported an associa-
tion between type 2 diabetes and elevated haematocrit,
which is thought to negatively affect nitric oxide availabil-
ity resulting in cardiovascular disease [23]. Furthermore,
increase of whole blood viscosity due to increased levels
of haematological parameters such as fibrinogen has been
reported in type 2 diabetic patients with arteriosclerosis
obliterans [24]. We are not aware of any study at the pri-
mary care settings in the Caribbean population that eval-
uated the prevalence of anaemia, high haematocrit or
increased whole blood viscosity in individuals with type 2
diabetes. In contrast to the elevated haematocrit report
[23], our study found high prevalence rates of anaemia in
diabetic patients, irrespective of gender. This finding may
be indicative of early renal disease given that previous
studies showed earlier appearance of anaemia in diabetic
patients; with an inverse relationship between creatinine
concentration and haemoglobin levels [12,13]. However,
it should be noted that macro-vascular, and not micro-
vascular, complication is commoner in type 2 diabetes
[19] and as such there appears to be little or no docu-
mented report of kidney complications in type 2 diabetes
in our population. Although there was a report of two
Afro-Caribbean teenagers with end-stage renal disease
who presented in clinics with anaemia [14], incidence or
prevalence of diabetic patients with anaemia are scanty.
In this study, anaemia was more prevalent amongst the
diabetic patients than non-diabetic subjects and the
former group of subjects were previously shown to have a
high prevalence of the metabolic syndrome [15]. The lim-
itation is that the study was not designed to determine the
type of anaemia the patients had, though iron-deficiency
anaemia is common in some other developing countries
[25,26]. Thus, diabetic patients and the senior citizens,
Table 2: Between-gender comparison of the haematological tests of the diabetic and non-diabetic subjects
Haematology profile Type 2 diabetic patients Non-diabetic subjects
Males Females Males Females
Age (years) §68.9 ± 1.2 64.6 ± 1.2¶ 48.9 ± 1.4 48.8 ± 1.8
Whole Blood Count (× 103/uL) 5.5 ± 0.3 6.0 ± 0.1 5.5 ± 0.2 5.5 ± 0.3
Red Blood Cell (× 106/uL) §§4.6 ± 0.1 4.4 ± 0.1 5.1 ± 0.1** 4.6 ± 0.1
Haemoglobin (g/dl) §§12.9 ± 0.2 12.1 ± 0.1¶ 14.6 ± 0.3** 12.5 ± 0.2
Hematocrit (%) §39.4 ± 0.5 37.5 ± 0.3 44.2 ± 0.7** 39.0 ± 0.5
Mean Corpuscular Volume (FL) 87.0 ± 0.7 85.3 ± 0.6¶ 87.4 ± 1.4 84.4 ± 1.3
Mean Corpuscular Haemoglobin (pg) 28.5 ± 0.3 28.2 ± 0.6 28.8 ± 0.5* 27.1 ± 0.5*
Platelet Count (× 103/uL) 224.2 ± 9.9 244.4 ± 5.7 237.9 ± 13.8 262.2 ± 10.1
Mean Platelet Volume (Fl) 11.1 ± 0.1 11.1 ± 0.1 11.2 ± 0.2 10.9 ± 0.2
*P < 0.05, **P < 0.001 for comparisons between male and female non-diabetic subjects
¶P < 0.05 for comparisons between male and female diabetic patients
§P < 0.05, §§P < 0.001 for comparisons between male diabetic and male non-diabetic subjects
P < 0.05, P < 0.001 for comparisons between female diabetic and female non-diabetic subjects
Table 3: Glycaemic control and levels of kidney function in patients with and without anemia
Type 2 diabetic patients Non-diabetic subjects
Anemia
N = 72
No Anemia
N = 83
Anemia
N = 8
No Anemia
N = 43
Glycated hemoglobin (%) 7.7 ± 0.3 7.6 ± 0.2 5.7 ± 0.2¶ 5.9 ± 0.2
Fasting plasma glucose (mmol/L) 9.3 ± 0.6 9.1 ± 0.4 4.6 ± 0.1¶ 5.0 ± 0.2
Creatinine (mg/dl) 1.4 ± 0.1 1.0 ± 0.03** 1.0 ± 0.1¶ 1.1 ± 0.02
Glomerular filtration rate (ml/min/1.73 m2)
(index of kidney function)
67.1 ± 3.0 87.9 ± 5.4** 86.2 ± 5.1¶ 82.6 ± 2.1
Chronic kidney disease (%)
(estimated GFR < 60 ml/min per 1.73 m2)
27 (38.6) 9 (10.8)** 1 (12.5) 1 (2.4)
**P < 0.001 for comparisons between diabetic patients with and without anaemia
¶P < 0.05 for comparisons between diabetic patients with anaemia and non-diabetic subjects with anaemiaCardiovascular Diabetology 2008, 7:25 http://www.cardiab.com/content/7/1/25
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with limited food choices, would be more vulnerable to
iron-deficiency anaemia and all cause mortality [11]. The
findings in the present study have implications for diabe-
tes management in that they appear to indicate a need for
routine full blood counts in primary care diabetes man-
agement. Intervention with erythropoietin has been
shown to improve the quality of life for anaemic patients
in chronic renal failure [25]. For diabetic patients, it is
well documented that reducing blood glucose levels and
targeting acceptable glycated haemoglobin (HbA1c) lev-
els have been the focus so as to prevent the risk of micro-
and macro-vascular complications [19,27,28]. Even then,
the reality is that most patients with type 2 diabetes in
developed and developing countries have glycated hae-
moglobin levels above the recommended target levels and
are prone to macro-vascular complications [2,3]. Inade-
quate or absence of laboratory facilities at the primary care
settings in many developing countries is a major limita-
tion in routine laboratory assessment of diabetic patients.
We believe that early detection and management of anae-
mia in diabetic patients at the primary care setting would
be cost effective in so far as it would reduce hospital
admissions and maintain optimum health. This could be
achieved through the provision of adequate laboratory
facilities and expansion of the scope of laboratory investi-
gations used in the management of diabetic patients.
Therefore, it is suggested that all diagnostic laboratories in
developing countries and elsewhere should include com-
plete blood count as one of the routine laboratory tests
required in the management of diabetic patients.
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